The potential therapeutic value of DGK inhibitors in the treatment of tumors and hematological diseases has led our group to develop new DGKA-specific inhibitors [22,23] and explore pan-cancer studies to identify potentially sensitive tumor types. Here, DGKB is linked to neoplasm.